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Abstract
Background: Mammalian target of rapamycin (mTOR) represents a key downstream intermediate for a
myriad of oncogenic receptor tyrosine kinases. In the case of the insulin-like growth factor (IGF) pathway,
the mTOR complex (mTORC1) mediates IGF-1 receptor (IGF-1R)-induced estrogen receptor alpha (ERα)
phosphorylation/activation and leads to increased proliferation and growth in breast cancer cells. As a
result, the prevalence of mTOR inhibitors combined with hormonal therapy has increased in recent years.
Conversely, activated mTORC1 provides negative feedback regulation of IGF signaling via insulin receptor
substrate (IRS)-1/2 serine phosphorylation and subsequent proteasomal degradation. Thus, the IGF pathway
may provide escape (e.g. de novo or acquired resistance) from mTORC1 inhibitors. It is therefore plausible
that combined inhibition of mTORC1 and IGF-1R for select subsets of ER-positive breast cancer patients
presents as a viable therapeutic option.
Methods: Using hormone-sensitive breast cancer cells stably transfected with the aromatase gene (MCF-7/AC-1),
works presented herein describe the in vitro and in vivo antitumor efficacy of the following compounds: dalotuzumab
(DALO; “MK-0646”; anti-IGF-1R antibody), ridaforolimus (RIDA; “MK-8669”; mTORC1 small molecule inhibitor) and
letrozole (“LET”, aromatase inhibitor).
Results: With the exception of MK-0646, all single agent and combination treatment arms effectively inhibited
xenograft tumor growth, albeit to varying degrees. Correlative tissue analyses revealed MK-0646 alone and in
combination with LET induced insulin receptor alpha A (InsR-A) isoform upregulation (both mRNA and protein
expression), thereby further supporting a triple therapy approach.
Conclusion: These data provide preclinical rationalization towards the combined triple therapy of LET plus
MK-0646 plus MK-8669 as an efficacious anti-tumor strategy for ER-positive breast tumors.
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Background
The mammalian target of rapamycin (mTOR) is a mas-
ter regulator of nutrient sensing (mTORC2) and growth
factor signaling (mTORC1) in normal cells and its dys-
function is implicated in the malignant transformation
for a variety of cancer types. As activation of mTOR
can confer primary resistance to endocrine therapy, a
number of prospective clinical trials (Phase II and III)
have reported improved survival benefit for hormone
receptor-positive breast cancer patients receiving hor-
mone therapy in combination with an mTOR inhibition
[1]. However, secondary resistance to mTOR inhibitors
remains problematic as suppression of negative feed-
back inhibition via mTORC1 blockade can induce the
IGF type-1 receptor (IGF-1R) and subsequently in-
crease both PI3K and MAPK signaling cascades [2, 3].
The completion of three recent clinical trials, two of
which specifically examined MK-0646 and MK-8669,
reinforce the added value of targeting IGF-1R in con-
junction with mTOR in advanced hormone receptor-
positive breast cancer tumors. In a recent report, Di
Cosimo and colleagues recently reported that the combin-
ation of dalotuzumab (DALO; “MK-0646”; anti-IGF-1R
antibody) and ridaforolimus (RIDA; “MK-8669”; mTOR
inhibitor) had evidence of antitumor activity in estrogen
receptor positive (ER+)/proliferative breast cancer patients
that were refractory to multiple chemotherapy regimens.
Additional findings from this study suggest that more
aggressive ER-positive luminal B subtype tumors exhib-
ited high IGF signaling activation and low RAS pathway
activation and that combined MK-8669/MK-0646 com-
bination therapy may be most appropriate for this sub-
set of patients. These data suggest that combination
MK-0646 and MK-8669 may be a promising new regi-
men for ER-positive breast cancer patients whom may
have limited benefit from hormonal therapy [4].
To determine the potential anti-tumor benefit of MK-
0646 as an effective adjuvant to combination LET and/or
MK-8669, xenograft studies were performed in athymic
nude mice bearing tumors of hormone-sensitive breast
cancer cells stably transfected with the aromatase gene
(MCF-7/AC-1). Both in vitro and in vivo correlative
samples were interrogated post-treatment to assess total
and/or phosphorylated protein expression (e.g. AKT,
S6K1, IGF-1R, MAPK, etc.) post drug administration. In
addition, insulin receptor isoform expression was evalu-
ated by qPCR for select treatment subsets. With the
exception of MK-0646, all treatments were effective in
suppressing tumor growth compared with controls.
While MK-8669 further enhanced LET-induced growth
inhibition, MK-0646 was less effective than LET alone
and LET +MK-0646 was similar to LET alone, likely due
to upregulation of InsR-A (confirmed by qPCR and
western blot analysis). Insulin signaling through mTOR
can be inhibited by the addition of MK-8669, which
enhances this activity. Abrogated p70S6K1 and in-
creased Akt phosphorylation confirmed MK-8669
target inhibition. RNAseq analysis revealed MK-0646
alone significantly downregulated IGF/Ins signaling
pathway compared to the untreated control tumors
and the triple therapy (LET +MK-8669 + MK-0646)
significantly impaired the DNA damage repair path-
way. While MK-0646 did not significantly enhance
LET +MK-8669 tumor growth inihibition, the triple
therapy was the most effective therapy in vivo to fur-
ther support its utility in aggressive ER-positive breast
cancer tumors.
Methods
Cell lines and reagents
Phenol red–free modified IMEM, DMEM, penicillin/
streptomycin solution, 0.05 % trypsin-EDTA solution,
Dulbecco's PBS, and geneticin (G418) were obtained
from Life Technologies. Fetal bovine serum (FBS) and
charcoal/dextran–treated FBS were obtained from
Hyclone. Androstenedione, tamoxifen (for in vivo use),
and hydroxypropyl cellulose were obtained from Sigma
Chemical Co (St. Louis, MO). Matrigel was purchased
from BD Biosciences. Enhanced chemiluminescence [5]
kits were purchased from Amersham Biosciences. IGF-1
was purchased from GroPep. Antibodies against p-
MAPK, MAPK, AKT, p-AKT, IGF-IRβ and p-IGF-IRβ
were purchased from Cell Signaling Technology. An anti-
body against β-actin was purchased from Sigma-Aldrich.
Horseradish peroxidase–conjugated anti-mouse and
anti-rabbit secondary antibodies were purchased form
Invitrogen. Antibody against insulin Rβ was purchased
from Santa Cruz Biotechnology. MCF-7 human breast
cancer cells stably transfected with the human aroma-
tase gene (MCF-7/AC-1 cells) were kindly provided by
Dr. Angela Brodie and Shiuan Chen (Beckman
Research Institute of City of Hope, Duarte, California)
as previously reported [6]. Letrozole was purchase from
LKT Laboratories, Inc. (Cat# L1878, St Paul, MN,
USA). Cells were routinely maintained in DMEM with
10 % fetal bovine serum, 1 % penicillin/streptomycin
solution, and 750 ug/mL G418, the culture medium
changed twice weekly and origin authenticated by
Genetica DNA Laboratories Inc. at the time of study.
Immunoblotting
For in vitro studies, MCF-7/AC-1 cells were cultured in
IMEM steroid–reduced medium without phenol red for
24 h prior to treatment initiation with one or more of
the following: vehicle control (DMSO), MK-0646 (5, 10
&15 μg/ml), MK-8669 (1, 2 & 3 μmol/L) and Letrozole
under serum-free conditions. After 24 h, IGF-1 (10nM)
was added to cells for 10 min. Lysates were prepared
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and analyzed by immunoblot analysis as previously de-
scribed [7]. Briefly, proteins were extracted from the cell
culture lysate or tumor tissues by homogenization in
buffer containing 50 mM Tris (pH 7.4), 1 mM EDTA,
150 mM NaCl and proteinase inhibitors (1 μg/ml phenyl-
methylsulfonyl fluoride, 10 μg/ml aprotinin and 1 μg/ml
leupeptin). Homogenates were centrifuged at 2000 g for
15 min at 4 °C. After centrifugation at 10,000 x g for
5 min, the supernatants were separated and their protein
concentrations were measured. The supernatants were
separated by 10 % SDS-PAGE, transferred onto Immuno-
Blot polyvinylidene difluoride (PVDF) membrane (catalog
no. 162–0177, Bio-Rad), and Western blot analysis was
performed. Membranes were blocked with 5 % milk in
TBS (10 mM Tris–HCl (pH 8.0) and 150 mM NaCl)
plus 0.05 % Tween-20 overnight at 4 °C prior to pri-
mary (24 h) and subsequent secondary (1 h) antibody
exposure. Proteins of interest were detected using an
ECL kit (Amersham, Arlington Heights, IL).
Clonogenics
Colony-forming assays were used to assess drug effect
on cell proliferation. In short, 500 cells obtained after
trypsinizing subconfluent cell culture stocks of MCF-7/
AC-1 were seeded in 35 mm tissue culture plates (in
triplicate) and allowed to adhere overnight. The plated
cells were treated with DMSO/diluent (0.1 %) or MK-
0646, MK-8669 or MK-0646 plus MK-8669 at the indi-
cated concentrations under serum-free conditions.
MCF-7/AC-1 cells were treated with IGF-1 100 nano-
gram/ml during drug exposure. Following three days of
treatment, plates were washed with PBS and media
replaced with DMEM (10 % fetal bovine serum, 1 %
penicillin/streptomycin solution. The plated cells were
allowed to proliferate to form colonies for 7 days. Then
plates were washed with PBS, stained with Coomassie
blue, and colonies counted on the G:BOX imager system
using GeneTools software (Syngene). Results were evalu-
ated graphically using GraphPad PRISM software. Each
presented figure is a representative of one of at least
three independent experiments, each performed in tripli-
cate. The method of Chou and Talalay was used to
determine synergy as described previously [8]. Median
effect analysis was done using Calcusyn software (Bio-
soft). With this method, a combination index (CI) > 1 is
deemed antagonistic, a combination index < 1 is syner-
gistic, and combination index = 1 is considered additive.
Surface response contours and modeling were carried
out in MATLAB as previously described [9].
Xenograft studies
Female ovariectomized BALB/c athymic nude mice 4–
6 weeks of age were obtained from Harlan Laborator-
ies (Indianapolis, IN) and housed in a pathogen-free
environment. All animal studies and experiments de-
scribed herein were carried out and approved accord-
ing to the guidelines of the Mayo Clinic Institutional
Animal Care and Use Committee. Animals were
allowed to acclimatize for ≥ 48 h prior to tumor im-
plantation. MCF-7/AC-1 cells were cultured to sub-
confluency and suspended in Matrigel (10 mg/mL) at
a concentration of 2.5 × 107 cells/mL for subcutaneous
flank injection (100uL). Mice were randomized to
their respective treatment groups using JMP (SAS,
Cary, NC) as tumors reached the appropriate size
(~250 mm3). Tumors were measured weekly with cali-
pers, and volumes calculated according to the follow-
ing formula: 4/3π x r12 x r2 (r1 < r2), where r1 is the
smaller radius. The nonsteroidal aromatase inhibitor
Letrozole (10ug/day) and antiestrogen tamoxifen (500 μg/
day) were prepared as suspensions (0.3 % hydroxypropyl
cellulose) and administered subcutaneously (daily) for
28 days. Dalotuzumab (DALO; “MK-0646”: anti-IGF-1R
antibody) was administered weekly via IP injection at a
dose of 20 mg/kg for a total of 4 weeks. Ridaforolimus
(RIDA; “MK-8669”; mTOR inhibitor) was administered IP
at a dose of 1 mg/kg for five continuous days (QDx5) for
total 4 weeks. All groups were subcutaneously supple-
mented with daily androstenedione (100 ug) for the
experimental duration as previously described [10]. Mice
were monitored daily and weighed once per week. Tumor
volume change was calculated when the treatment period
was finished, TVC = (ΔT / ΔC) x 100, where ΔT stands for
mean tumor volume change of each treatment group and
ΔC for mean tumor volume change of control group.
Tumor volume and body weight data were analyzed by
one-way ANOVA test (GraphPad). At the time of eu-
thanasia, tumors were rapidly excised, weighed and
preserved for downstream correlative analyses as snap-
frozen and in RNA Later (Invitrogen Life Technologies,
Carlsbad, CA, USA).
Quantitative PCR
Total RNA was isolated using Trizol reagents
(Cat#15596-026, Invitrogen, Carlsbad, CA). RNA was re-
verse transcribed using ABI High capacity RNA to
cDNA kit (Applied Biosystem, Carlsbad, CA) as per the
manufacturer’s instructions. Sample RNA quality was
assessed within each group post reverse-transcriptionally
through ribosomal protein 19 (RPL19) expressions.
Normalization ratios for each sample were calculated
(Nsample = RPL19median/RPL19sample) and compared
to the group mean. Samples with RPL19 normalization
ratios greater than +3.5 standard deviations (SD) (ap-
proximately 99.9 % confidence interval) from the mean
were excluded from further analysis. The standard repli-
cates for each qPCR assay were examined for amplifica-
tion efficiencies between 95–105 % and all standards
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and sample replicate data were analyzed for product spe-
cific melt cures. Sample or standard replicates which did
not conform to these parameters were removed from
the analysis. Gene transcript copy numbers from each
conforming replicate were normalized to RNA input and
RPL19 gene expression before being reported as copies
of target gene per μg RNA as previously described [11].
RNA-seq
MCF-7/AC-1 xenograft tumor RNA integrity was con-
firmed using the Agilent 2100 Bioanalyser (Agilent
Technologies, USA) and next-generation sequencing
was performed at Merck Co using the Illumina Hiseq
2000 platform (paired-end sequencing, 100 base pairs).
RNA-seq data was analyzed with Partek Flow as previ-
ously described. Briefly, reads were mapped to the hu-
man genome (Ensembl GRCh37) and quantified using
the STAR aligner, aligned reads to genes using Partek
E/M and differentially expressed genes determined
using gene-specific analysis (GSA).
Results
IGF-1R inhibition (MK-0646) does not enhance hormonal
therapy (letrozole or tamoxifen) in MCF-7/AC-1 xenografts
Based on our previous investigations demonstrating en-
hanced activity of hormonal therapy in combination
with IGF inhibition, the in vivo anti-tumor potential of
MK-0646 plus letrozole (LET) or tamoxifen (TAM) was
determined [10] (Fig. 1). MCF-7/AC-1 xenografts were
established and as tumors reached the appropriate size
(250 mm3) mice were randomized to one of the
following treatment cohorts (n ≥ 4 mice/cohort) for a
duration of 28 days: Control (vehicle alone), TAM, LET,
MK-0646, TAM +MK-0646, LET +MK-0646. Hormo-
nal therapy alone significantly inhibited tumor growth
as compared to control and LET was superior to TAM
in terms of percent inhibition (34.6 vs. 28.6 %) and stat-
istical significance (P < 0.001 vs. P < 0.05). While MK-
0646 alone did not significantly inhibit tumor growth,
the combination LET +MK-0646 was more effective
than combination TAM +MK-0646 (41.7 vs. 30.9 %)
and resulted in the greatest degree of tumor growth in-
hibition. Of note, all treatments were well tolerated as
bodyweight was maintained throughout study duration
(data not shown).
MK-0646 increases Insulin Receptor A Isoform expression
in MCF-7/AC-1 xenografts
In contrast to a small molecule inhibitor targeting IGF-
1R and insulin receptor (IR), MK-0646 failed to improve
anti-tumor response to hormonal therapy in ER-positive
breast cancer xenografts (Fig. 1). To delineate potential
compensatory mechanisms, post-treatment tumors were
assessed for IGF1R and IR isoform gene expression
(Fig. 2). MK-0646 significantly increased both IGF1R
and IR isoform gene expression, IRB to a lesser extent as
compared to IRA (Fig. 2a). While the addition of hormo-
nal therapy had little impact, overall IRA expression was
highest in LET +MK-0646 tumors (Fig. 2a). MK-0646
induces receptor internalization, leading to subsequent
degradation and a reduction in IGF-1R protein levels.
Treatments with LET and/or MK-0646, as in Fig. 1, were
repeated, but were also terminated at days 7 and 14 days
to investigate potential temporal modulations in recep-
tor expression (Fig. 2b). Regardless of time point, IGF-
1R expression was markedly reduced in all MK-0646
treatment cohorts. While MK-0646 alone decreased IR
expression, the combination LET +MK-0646, following
an initial decline at Days 7 and 14, resulted in the high-
est level of IR expression at Day 28. Statistical analyses
for IGF1R, IRA and IRB are included (Additional file 1:
Table S1; Additional file 2: Table S2; Additional file 3:
Table S3).
Persistent mTOR signaling in response to IGF-1R
inhibition is overcome by MK-8669
Based on the aforementioned finding where MK-0646
upregulated IRA levels, potential compensatory mecha-
nisms (e.g. IR signaling via mTOR) resulting from IGF-
1R/ER-targeted inhibition were examined (Fig. 3). Prior
to IGF-induced IGF-1R activation, serum-starved MCF-
7/AC-1 cells were incubated for 24 h with LET and/or
increasing concentrations of MK-0646 and/or MK-8669
(Fig. 3a). As expected, IGF-1 ligand resulted in robust
IGF-1R phosphorylation in MCF-7/AC-1 cells. MK-
Fig. 1 IGF-1R inhibition (MK-0646) does not enhance hormonal therapy
(letrozole or tamoxifen) in MCF-7/AC-1 xenografts. Ovariectomized
female nu/nu mice between the ages of 7–8 weeks old were inoculated
with MCF-7/AC-1 tumor cells in each flank and immediately
supplemented with androstenedione (100 μg/day). Once bilateral
flank tumors (both left and right) reached the appropriate size
(250–300 mm3), mice were randomized (n ≥ 8 mice/cohort) and
the appropriate treatments initiated (control, MK-0646, letrozole
(LET), LET + MK-0646, tamoxifen (TAM), TAM + MK-0646) for a total
of 28 days. Tumor volumes were measured twice weekly and depicted
as percent change relative to day 0. Error bars represent SEM and
results are representative of three independent experiments
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0646, alone or in combination with LET, prevented IGF-
induced IGF-1R, Akt and MAPK phosphorylation but
induced S6K1 activation. Inhibition of upstream mTOR
via MK-8669 effectively blocked S6K1 phosphorylation
and in conjunction with previous findings, increased
AKT phosphorylation likely via negative feedback loops
secondary to mTOR inhibition. More importantly, com-
bination LET +MK-0646 +MK-8669 resulted in the
most profound inhibition of IGF-1R/IR, AKT, MAPK
and S6K1.
In an effort to simulate IR-A overexpression and its
subsequent compensatory activation in response to MK-
0646, IGF-2 (known to activate IR-A) was overexpressed
(MCF-7/AC-1/IGF-2) and the aforementioned drug
combinations were tested (Fig. 3b). As a negative con-
trol, IGF-1 did not induce IGF-1R activation. The effects
of single agent MK-0646 and MK-8669 were similar to
the parental cells in terms of phosphorylated IGF-1R/IR,
Akt and S6K1. Although both inhibitors increased
MAPK phosphorylation, combination MK-0646 +MK-
8669 effectively restored basal levels of both MAPK and
IGF-1R/IR phosphorylation. In contrast to MK-8669,
where the addition of LET had no effect, MAPK quies-
cence was achieved following LET +MK0646 treatment.
With the exception of MAPK, the triple combination
LET +MK-0646 +MK-8669 remained highly effective
towards downstream signaling blockade. These data
indicate IR-A-induced signaling as a potential escape
pathway to IGF/mTOR/ER inhibition. Additional efforts
are currently underway to better understand the dynamic
signaling interactions in parental vs. MCF-7/AC-1/IGF-2
cells.
MK-0646 and MK-8669 synergistically inhibit clonogenesis
Based on the above findings, the synergistic potential of
combined mTOR/IGF-1R inhibition was examined
(Fig. 4). Specifically, colony formation in response to in-
creasing doses of MK-0646, MK-8669 or the combin-
ation MK-0646 +MK-8669 was determined in MCF-7/
AC-1 and MCF-7/AC-1/IGF-2 cells (Fig. 4a). MK-0646
alone elicited little (MCF-7/AC-1) to no effect (MCF-7/
AC-1/IGF-2). Conversely, MCF-7/AC-1/IGF-2 cells were
more sensitive to MK-8669 (IC50 = 5.9nM vs. 27.2nM).
While the combination resulted in synergy across cell
lines, the magnitude of synergy varied as combination
index (CI) values were superior in MCF-7/AC-1 vs.
MCF-7/AC-1/IGF-2 cells (e.g. 0.062 vs. 0.251). Surface
response modeling was employed to illustrate the syner-
gistic potential of MK-0646 +MK-8669 in MCF-7/AC-1
cells (Fig. 4b). These data support multiplicative benefit
of adding MK-0646 to existing MK-8669 in ER-positive
breast cancer cells and further implicate the IGF-2/IR-A
signaling axis as a potential resistance pathway. The
remaining works presented herein center upon elucidat-
ing the in vivo impact and correlative molecular reper-
cussions of said targeted therapies in parental MCF-7/
AC-1 xenografts.
In vivo activity of LET +/− MK-8669 +/− MK-0646 in
MCF-7/AC-1 xenografts
To determine if the described in vitro MK-0646 +MK-
8669 synergy translated in vivo, established MCF-7/
AC-1 xenografts were allowed to reach the appropriate
size (250 mm3) and mice randomized to one of the follow-
ing 28-day treatment cohorts (n ≥ 7 mice/cohort): Control,
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Fig. 2 MK-0646 increases Insulin Receptor A Isoform expression in
MCF-7/AC-1 xenografts. MCF-7/AC-1 xenograft tumors were harvested
and immediately flash frozen following 28 days of treatment (Fig. 1).
RNA and protein were extracted for Insulin Receptor and IGF-1R
quantification by qPCR (a) and western blot analysis (b) as described
in the methods. a Absolute IGF1R (Top) and IRA/B isoform (Bottom)
copy number normalized to RPL19 housekeeper. b Protein from pooled
group replicates isolated at indicated time points were subject to
western blotting with indicated antibodies, as described in Materials
and Methods section. Error bars represent SEM. *, P < 0.05; **, P < 0.01;
***, P <0.001; **** P < 0.0001
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MK-0646, LET +MK-8669 or LET +MK-0646 +MK-
8669. While the impact of MK-0646 on tumor growth
remained negligible, single agent MK-8669 and LET led to
significant tumor regression compared to untreated
control (Fig. 5a). Although not significant compared to
LET +MK-8669, the triple combination LET +MK-
8669 +MK-0646 led to the largest numerical regression
compared to untreated control tumors (62.7 % reduc-
tion). Statistical analyses comparing treatment cohorts
are included (Additional file 4: Table S4). In addition,
all agents (both alone and in combination) were well
tolerated, as bodyweight did not significantly differ
across cohorts throughout treatment duration (data not
shown).
To investigate the biochemical effect(s) of the afore-
mentioned therapies, post treatment tumors were har-
vested at treatment end (Day 28) and subjected to
western blotting (Fig. 5b). As demonstrated in vitro,
single agent efficacy was confirmed as MK-0646 down-
regulated IGF-1R and MK-8669 resulted in both de-
creased S6K1 phosphorylation and, albeit to a lesser
extent, increased Akt phosphorylation. In addition,
MK-8669 led to increased IGF-1R/IR phosphorylation
and MK-8669 +MK-0646 further enhanced levels, the
result(s) of which may be attributable to IR compensa-
tion. Compared to LET +MK-8669, the triple combin-
ation LET +MK-8669 +MK-0646 was most effective in
terms of decreased total IGF-1R and phosphorylated
IGF-1R/IR, Akt, S6K1 and MAPK. These data support
co-targeting IGF-1R and mTOR in ER-responsive
breast cancer.
RNA-seq analysis reveals both overlapping and distinct
gene regulation in MCF-7/AC-1 xenografts
To better understand the transcriptional impact and po-
tential changes in the molecular landscape resulting
from targeted IGF-1R, mTOR and ER inhibition, an un-
biased, comprehensive analysis of post-treatment tumors
by RNA-seq was performed (Fig. 6). A complete list of
all treatment-induced gene expression changes accord-
ing to directional magnitude are included (Additional
file 5: Table S5). As opposed to in vivo tumor repression,
where single agent LET and MK-8669 were significantly
better than MK-0646, ER (51 genes) and mTOR (160
genes) inhibition altered few genes compared to IGF
blockade (1,163 genes). However, when combined with
MK-0646
MK-8669
LET +++++++++ +- - - - - - - - - -
---- - - - -
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Fig. 3 Persistent mTOR signaling in response to IGF-1R inhibition is overcome by MK-8669. Western Blot analysis of MCF-7/AC-1 (a) and MCF-7/
AC-1/IGF-2 (b) cells treated with one or more of the following agents for 24 h at the indicated dose(s): LET (1uM), MK-0646 (1.25, 2.5, 5 ng/uL)
and/or MK-8669 (100, 500, 1000 nM). IGF-1 was added for 10 min prior to harvest for the indicated samples
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one another, major increases were observed (e.g. 1,711
genes in LET +MK-8669). In an effort to better under-
stand gene expression changes across cohorts, treat-
ments were normalized to controls and presented as a
multi-set Venn diagram (Fig. 6a). Depending on the con-
trast, overlapping (e.g. LET +MK-8669 vs. LET +MK-
8669 +MK-0646) or distinct (e.g. LET +MK-8669 vs.
LET +MK-8669 +MK-0646) gene expression patterns
B
A 
Fig. 4 MK-0646 and MK-8669 synergistically inhibit clonogenesis. a MCF-7/AC-1 (Top) and MCF-7/AC-1/IGF-2 (Bottom) cells were exposed to
increasing concentrations of MK-8669 (closed squares), MK-0646 (closed triangles) or the combination MK-8669 + MK-0646 (closed diamonds)
and assessed for colony outgrowth (normalized to control). Synergy is indicated by combination index (CI) values, where < 1 is synergistic.
Error bars represent SEM and results representative of three independent experiments. b Surface response modeling was employed to demonstrate
the multiplicative benefit of adding MK-8669 to existing MK-0646 or vice versa. MCF-7/AC-1 cells were treated with MK-0646 (x-axis), MK-8669 (y-axis)
or the combination (z-axis) at varying doses. Percent inhibition is depicted as the fraction affected (Fa)
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were observed. A heatmap depicting the most signifi-
cantly regulated genes in the LET +MK-8669 +MK-
0646 cohort illustrate the co-regulatory nature (both
direction and magnitude) with LET +MK-8669 (Fig. 6b).
Upon close examination, the majority of downregulated
genes have been linked a more aggressive breast tumor
phenotype. However, numerous upregulated genes have
associated with breast tumor progression and metasta-
sis, suggesting possible compensatory transcriptional
alterations to overcome treatment-induced anti-tumor
effects.
Functional analysis was performed in IPA (Ingenuity
Pathway Analysis) was performed to assess global tran-
scription (Additional file 6: Table S6). Although MK-
0646 was the only treatment that failed to inhibit in vivo
tumor growth, antibody efficacy was first confirmed as
‘IGF-1 Signaling’ was predicted as a significantly inhib-
ited pathway in the MK-0646 cohort. Using p-value and
z-score, the ‘The Role of BRCA1 in DNA Damage
Response’ was predicted as the top canonical pathway
across treatments (Additional file 7: Figure S1). A heat-
map of pathway-specific genes within each treatment
confirmed that DNA damage response was most
impaired in the LET +MK-8669 +MK-0646 cohort
(Additional file 8: Figure S2). Therefore, combined ER/
mTOR/IGF targeting may greatly sensitize tumors to
DNA-damaging agents (e.g. standard chemotherapy) and
as a result, efforts to test the triple therapy with standard
of care chemotherapies are being explored.
Discussion
A plethora of preclinical data supports targeted inhib-
ition of the IGF pathway across numerous cancer types
[12]. Unfortunately, a general lack of activity is a com-
mon stigmata of IGF-1R inhibitors in breast cancer [13].
To highlight this point, a randomized, controlled,
double-blind, phase 2 trial examining the potential bene-
fit of adding the IGF-1R inhibitor ganitumab (AMG
479) to hormonal therapy in patients with hormone-
receptor positive breast cancer reported negative results
[14]. The failure of ganitumab and other IGF-targeting
agents has been widely attributed to poor patient selec-
tion (e.g. lack of predictive biomarkers) and/or unfore-
seen compensatory signaling networks (e.g. HER, IR,
IGFBPs) [15–18]. As a result, additional studies to iden-
tify, and potentially target, the key factors mediating
anti-IGF-1R resistance are of high interest in the field of
oncology.
Targeting of the IGF-1R promotes receptor tyrosine
kinase cross-talk and leads to the subsequent compensa-
tory activation of a myriad of downstream signaling
molecules known to play a role in resistance and tumori-
genic behavior(s). IR represents the closest relative to
IGF-1R and is linked to anti-IGF-1R monoclonal anti-
body resistance via heterodimer formation (IGF-1R:IR)
and/or IGF-2/IRA signaling as IRA is commonly present
in a variety of solid tumors [19–21]. The fetal or A iso-
form of the IR appears to have a more mitogenic role in
cancer cell proliferation than its purely metabolic iso-
form IRB [22]. The varying biological activities of IR iso-
forms likely relate to their differing affinities towards
IGF ligands. Specifically, the metabolic IRB binds only
insulin at physiologic concentrations, whereas the mito-
genic IRA is able to bind and be activated by IGF-2 [23].
Thus, IRA through dimerization with IGF-1R (IGF-
1R:IR) or homo-dimerization may provide mitogenic
stimuli to cancer cells via IGF-2 activation. Accumulated
data has implicated IRA, or the IR total content, as an
important factor in breast cancer outcome and impli-
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Fig. 5 In vivo activity of LET +/− MK-8669 +/− MK-0646 in MCF-7/
AC-1 xenografts. a As previously described, ovariectomized female
nu/nu mice between the ages of 7–8 weeks old were inoculated
with MCF-7/AC-1 tumor cells in each flank and immediately
supplemented with androstenedione (100 μg/day). Once bilateral
flank tumors (both left and right) reached the appropriate size
(250–300 mm3), mice were randomized (n ≥ 9 mice/cohort) and
the appropriate treatments initiated (Control, LET, MK-8669, MK-0646,
MK-8669 + MK-0646, LET + MK-0646, LET + MK-8669 or LET +
MK-0646 + MK-8669) for a total of 28 days. Tumor volumes were
measured weekly and depicted as percent change relative to day 0.
Error bars represent SEM and results are representative of two
independent experiments. b Tumors from treatment groups were
collected 28 days post treatment initiation, immediately snap frozen
and lysates pooled (n ≥ 3 samples/treatment cohort) for Western
Blot analysis
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therapies specifically targeting IGF-1R, namely monoclo-
nal antibody therapeutics. Patients with node negative
breast cancers whose tumors express high IR, compared
to even moderate IR content, report poor disease-free
survival intervals [24]. Early studies have also shown that
roughly 80 % of breast cancers have an IR content
higher than the median content found in the normal
breast and approximately 20 % of cancers present 10-
fold higher levels of IR levels than the median value of
normal breast tissue. Early studies targeting IGF-1R
receptor in patients with refractory tumors have demon-
strated that monoclonal antibody therapies may induce
upregulation of insulin secretion, thereby implicating it
as a compensatory mechanism that could possibly acti-
vate IR signaling as a mechanism of resistance [25].
While epithelial breast cancer cells commonly overex-
press IGF-1R, surrounding tumor-associated stroma
provides a rich source of IGF-2 [26]. Upon binding to
IGF-2, both IR-A and IGF-1R:IR hybrid receptors are
thought to promote proliferative and tumorigenic behav-
ior predominantly via MAPK and PI3K/Akt signaling,
both of which converge upon the mTOR/S6K1 axis as a
critical mediator of cell growth, survival and metabolism
[27]. Negative feedback inhibition of the IGF pathway
via canonically active mTOR/S6K1 effectively limits
IGF-1R signaling. As a result, mTOR inhibitors alleviate
IGF-1R repression and increase Akt activation as a
potential mechanism of resistance [3]. Moreover, a dy-
namic interplay between IGF and ERα in breast cancer
cells has been demonstrated, where IGF-1R increase
Fig. 6 RNAseq analysis reveals both overlapping and non-overlapping gene expression patterns in MCF-7/AC-1 xenografts. a Venn Diagram of
the overlapping and unique number of genes according to treatment cohort(s). b Heatmap depicting the most significantly up (red) and down
(green) regulated genes in LET + MK-8669 +MK-0646-treated tumors compared to the remaining treatment cohorts. Color bar indicates log-fold
expression change compared to control tumors
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ERα phosphorylation and activity via mTOR/S6K1 and
ERα mediates IGF-1R, IRS-1 and IGF ligand expression
[28]. Thus, combined IGF-1R/mTOR inhibition plus
hormone therapy in breast cancer cells presents as a
viable therapeutic option.
Conclusions
Data herein demonstrate that, similar to clinical trials, IGF-
1R inhibition (via MK-0646) does not enhance hormonal
therapy in ER-positive breast cancer cells, the results of
which are may be attributable to compensatory IGF-2/IRA
activity. Although IRA-induced signaling remains a poten-
tial confounder as a potential escape pathway, biochemical
and in vivo studies support combined IGF/mTOR/ER
inhibition. Importantly, for the first time, synergistic inhib-
ition is demonstrated when combining IGF-1R and mTOR
targeting agents in breast cancer cells. Finally, combined
IGF/mTOR/ER inhibition was most effective in limiting
tumor growth and markedly altered transcriptional activity
in ER-positive breast cancer tumors.
Additional files
Additional file 1: Table S1. Statistical analysis of IGF1R expression for
samples depicted in Fig. 1. (XLSX 44 kb)
Additional file 2: Table S2. Statistical analysis of IRA expression for
samples depicted in Fig. 1. (XLSX 44 kb)
Additional file 3: Table S3. Statistical analysis of IRB expression for
samples depicted in Fig. 1. (XLSX 44 kb)
Additional file 4: Table S4. Statistical analysis of final tumor volume for
samples depicted in Fig. 5. (XLSX 44 kb)
Additional file 5: Table S5. Gene expression values for all treatment
cohorts expressed as relative fold-change compared to control. (XLSX 623 kb)
Additional file 6: Table S6. Ingenuity Pathway Analysis. (XLSX 115 kb)
Additional file 7: Figure S1. Pathway inhibition of the ‘Role of BRCA1
in DNA Damage Response’ in LET + MK-8669 + MK-0646 tumors.
Highlighted in green are the significantly downregulated genes
compared to control tumors. (PDF 415 kb)
Additional file 8: Figure S2. Heatmap depicting DNA damage gene
expression across treatment cohorts. Color bar indicates log-fold expression
change compared to control tumors. (PDF 92 kb)
Abbreviations
DALO: Dalotuzumab; ERα: Estrogen receptor alpha; IGF: Insulin-like growth
factor; IGF-1R: IGF-1 receptor; InsR-A: Insulin receptor alpha A; IRS: Insulin
receptor substrate; LET: Letrozole; MTOR: Mammalian target of rapamycin;




Suported in part by the Mayo Clinic Breast SPORE (CA116201-03), National
Institutes of Health Endocrine Training Grant T32 DK07352 and Merck Co.
Availability of data and materials
RNA-seq data generated from xenograft breast cancer tumors were
submitted to Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/)
with accession number: GSE79492 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE79492).
Authors’ contributions
MAB, XH, BBH, SS, SJW and PH participated in the conception and design of
the study and the development of methodology. XH, PT and SCH performed
the experiments and acquired the data. MAB, XH, SJW and PH were involved
in the analysis and interpretation. MAB and BBH performed the bioinformatics
and biostatistics analyses. MAB, XH and PH contributed significantly to the
writing, review and/or revision of the manuscript. All authors provided critical
comments of the manuscript and have read and approved the final version of
the manuscript.
Competing interests
BBH and PH are employees of Merck & Co. SS is an employee of Jounce
Therapeutics, Inc. No non-financial conflicts of interest exist for any of the authors.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
2Molecular Oncology, Merck Research Laboratories, Boston, MA 02115, USA.
3Oncology unit, Department of Medicine, Rajavithi Hospital, Bangkok 10400,
Thailand. 4Division of Medical Oncology, Mayo Clinic College of Medicine,
200 First St. SW, Rochester, MN 55905, USA.
Received: 29 June 2015 Accepted: 7 October 2016
References
1. Vicier C, Dieci MV, Arnedos M, Delaloge S, Viens P, Andre F. Clinical
development of mTOR inhibitors in breast cancer. Breast Cancer Res. 2014;
16:203.
2. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al.
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-
dependent feedback loop in human cancer. J Clin Invest. 2008;118:3065–74.
3. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition
induces upstream receptor tyrosine kinase signaling and activates Akt.
Cancer Res. 2006;66:1500–8.
4. Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Brana I,
et al. Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R
Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I
Clinical Trial. Clin Cancer Res. 2015;21:49–59.
5. Timmermans F, Velghe I, Vanwalleghem L, De Smedt M, Van Coppernolle S,
Taghon T, et al. Generation of T cells from human embryonic stem cell-
derived hematopoietic zones. J Immunol. 2009;182:6879–88.
6. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase
complementary DNA in mammalian cells: a useful system for aromatase
inhibitor screening. Cancer Res. 1990;50:6949–54.
7. Hou X, Tan Y, Li M, Dey SK, Das SK. Canonical Wnt signaling is critical to
estrogen-mediated uterine growth. Mol Endocrinol. 2004;18:3035–49.
8. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the
combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme
Regul. 1984;22:27–55.
9. Kern SE, Xie G, White JL, Egan TD. A response surface analysis of propofol-
remifentanil pharmacodynamic interaction in volunteers. Anesthesiology.
2004;100:1373–81.
10. Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, et al. Dual IGF-
1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of
estrogen-dependent breast cancer. Cancer Res. 2011;71:7597–607.
11. Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P.
Quantifying insulin receptor isoform expression in FFPE breast tumors.
Growth Horm IGF Res. 2012;22:108–15.
12. Pollak M. Targeting insulin and insulin-like growth factor signalling in
oncology. Curr Opin Pharmacol. 2008;8:384–92.
13. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?
J Natl Cancer Inst. 2012;104:975–81.
14. Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, et al.
Ganitumab with either exemestane or fulvestrant for postmenopausal women
Becker et al. BMC Cancer  (2016) 16:814 Page 10 of 11
with advanced, hormone-receptor-positive breast cancer: a randomised,
controlled, double-blind, phase 2 trial. Lancet Oncol. 2013;14:228–35.
15. Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, et al.
IGFBP ratio confers resistance to IGF targeting and correlates with increased
invasion and poor outcome in breast tumors. Breast Cancer Res. 2012;18:
1808–17.
16. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. HER receptor
signaling confers resistance to the insulin-like growth factor-I receptor
inhibitor, BMS-536924. Mol Cancer Ther. 2008;7:2589–98.
17. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen
is associated with loss of the type I insulin-like growth factor receptor:
implications for breast cancer treatment. Cancer Res. 2012;72:3372–80.
18. King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of
IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 2014;40:1096–105.
19. Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, et al.
Heterodimerization of glycosylated insulin-like growth factor-1 receptors
and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS
One. 2012;7:e33322.
20. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally
enhances multistage tumor progression and conveys intrinsic resistance to
IGF-1R targeted therapy. Proc Natl Acad Sci U S A. 2010;107:10791–8.
21. Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ. Potent inhibition
of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is
reversed by IGF-2. Mol Cancer Ther. 2012;11:649–59.
22. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin
receptor activation by IGF-II in breast cancers: evidence for a new
autocrine/paracrine mechanism. Oncogene. 1999;18:2471–9.
23. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-
like growth factor I hybrid receptors have different biological characteristics
depending on the insulin receptor isoform involved. J Biol Chem. 2002;277:
39684–95.
24. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor
expression and clinical outcome in node-negative breast cancer. Proc Assoc
Am Physicians. 1997;109:565–71.
25. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I
dose escalation study of the anti insulin-like growth factor-I receptor
monoclonal antibody CP-751,871 in patients with refractory solid tumors.
Breast Cancer Res. 2007;13:5834–40.
26. Ellis MJ, Singer C, Hornby A, Rasmussen A, Cullen KJ. Insulin-like growth
factor mediated stromal-epithelial interactions in human breast cancer.
Breast Cancer Res Treat. 1994;31:249–61.
27. Malaguarnera R, Belfiore A. The insulin receptor: a new target for cancer
therapy. Front Endocrinol. 2011;2:93.
28. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates
ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol
Endocrinol. 2011;25:516–28.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Becker et al. BMC Cancer  (2016) 16:814 Page 11 of 11
